Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Core Insights - Adaptive Biotechnologies Corporation is focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [2] - The company will participate in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology, highlighting their clonoSEQ assay technology [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company that aims to leverage the adaptive immune system for disease diagnosis and treatment [2] - The company utilizes a proprietary immune medicine platform to decode the genetics of the adaptive immune system, enabling partnerships with biopharmaceutical companies and informing drug development [2] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, focusing on the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders [2]